

Resource Summary Report

Generated by [RRID](#) on Jul 29, 2026

BD Pharmingen™ FITC Mouse Anti-Human CD3 Clone UCHT1

RRID:AB_395739

Type: Antibody

Proper Citation

BD Biosciences Cat# 555332, RRID:AB_395739

Antibody Information

URL: http://antibodyregistry.org/AB_395739

Proper Citation: BD Biosciences Cat# 555332, RRID:AB_395739

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: BD Pharmingen™ FITC Mouse Anti-Human CD3 Clone UCHT1

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: UCHT1

Antibody ID: AB_395739

Vendor: BD Biosciences

Catalog Number: 555332

Record Creation Time: 20250820T054603+0000

Record Last Update: 20250820T222441+0000

Ratings and Alerts

No rating or validation information has been found for BD Pharmingen™ FITC Mouse Anti-Human CD3 Clone UCHT1.

No alerts have been found for BD Pharmingen™ FITC Mouse Anti-Human CD3 Clone UCHT1.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 28 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Kulkarni AJ, et al. (2025) L-Phenylalanine is a metabolic checkpoint of human Th2 cells. *Cell reports. Medicine*, 6(12), 102466.

Guthmiller JJ, et al. (2025) Long-lasting B cell convergence to distinct broadly reactive epitopes following vaccination with chimeric influenza virus hemagglutinins. *Immunity*, 58(4), 980.

Lin S, et al. (2025) Phase 1b/2 study of ADG106, a 4-1BB/CD137 agonist, in combination with toripalimab in patients with advanced solid tumors. *iScience*, 28(5), 112497.

Bian Q, et al. (2025) Maternal natural killer cells drive neuroimmune disorders in offspring through aberrant secretion of extracellular granzyme B. *Immunity*, 58(6), 1502.

Schweihof V, et al. (2025) Multiplexed immune profiling and 3D co-culture assays to assess the individual checkpoint therapy response in head and neck squamous cell carcinoma. *Frontiers in oncology*, 15, 1622008.

Koliesnik I, et al. (2025) An IL-12 partial agonist sustains intratumoral lymphocyte activation and detoxifies systemic IL-12 therapy. *Cell reports*, 45(1), 116757.

Zhang J, et al. (2024) Pyroptotic T cell-derived active IL-16 has a driving function in ovarian endometriosis development. *Cell reports. Medicine*, 5(3), 101476.

Bruss C, et al. (2024) Neoadjuvant radiotherapy in ER+, HER2+, and triple-negative - specific breast cancer based humanized tumor mice enhances anti-PD-L1 treatment efficacy. *Frontiers in immunology*, 15, 1355130.

Momenilandi M, et al. (2024) FLT3L governs the development of partially overlapping hematopoietic lineages in humans and mice. *Cell*, 187(11), 2817.

Neehus AL, et al. (2024) Human inherited CCR2 deficiency underlies progressive polycystic lung disease. *Cell*, 187(2), 390.

Valiate BVS, et al. (2024) Evaluation of an RBD-nucleocapsid fusion protein as a booster candidate for COVID-19 vaccine. *iScience*, 27(7), 110177.

Gao J, et al. (2024) Proteomic and metabolomic profiling of plasma predicts immune-related adverse events in older patients with advanced non-small cell lung cancer. *iScience*, 27(6), 109946.

Huang X, et al. (2024) Serum amyloid A facilitates expansion of CD4⁺ T cell and CD19⁺ B cell subsets implicated in the severity of myasthenia gravis patients. *Journal of neurochemistry*, 168(3), 224.

Albert V, et al. (2024) HER4 Affects Sensitivity to Tamoxifen and Abemaciclib in Luminal Breast Cancer Cells and Restricts Tumor Growth in MCF-7-Based Humanized Tumor Mice. *International journal of molecular sciences*, 25(13).

Luo Q, et al. (2023) Apatinib remodels the immunosuppressive tumor ecosystem of gastric cancer enhancing anti-PD-1 immunotherapy. *Cell reports*, 42(5), 112437.

Zhang Y, et al. (2022) Temporal molecular program of human hematopoietic stem and progenitor cells after birth. *Developmental cell*, 57(24), 2745.

Demaria O, et al. (2022) Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant. *Cell reports. Medicine*, 3(10), 100783.

Li SS, et al. (2022) HLA-B*46 associates with rapid HIV disease progression in Asian cohorts and prominent differences in NK cell phenotype. *Cell host & microbe*, 30(8), 1173.

Dejnirattisai W, et al. (2021) The antigenic anatomy of SARS-CoV-2 receptor binding domain. *Cell*, 184(8), 2183.

Abdul-Jawad S, et al. (2021) Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients. *Cancer cell*, 39(2), 257.